Phase II study of chemoradiation with TS-1 / Panitumumab as preoperative treatment in advanced rectal cancer.

Not Applicable

Recruiting

• Conditions: advanced rectal cancer

• Registration Number: JPRN-UMIN000007492
• Lead Sponsor: Juntendo University Faculty of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with a history of serious drug allergy. 2) Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 3) Patiens receiving flucytosine (a pyrimidine system antifungal agent fluoride). 4) Patients with active infection (fever over 38). 5) Patients with serious complications (intestinal paralysis, intestinal obstruction, interstitial pneumonia, pulmonary fibrosis, uncontrolled diabetes, uncontrolled hypertension, heart failure, renal failure, liver failure, etc.) 6) Patients with a history of interstitial pneumonia. 7) Patients with ascites, pleural effusion requiring treatment. 8) Patients with gastrointestinal bleeding. 9) Patients with diarrhea. 10) Patients with perforation, penetration. 11) Women with (making) the possibility of pregnancy, pregnant or lactating women. Patients with no intention to contraception. 12) Any other cases who are regarded as inadequate for study enrollment by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified